These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 36826087)
1. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. Chen Y; Zou X; Ma M; Liu Y; Wang R; Dai Z; Tashiheng Y; Yan Y; Yu X; Wang X; Liu C; Lin X; Cheng H Curr Oncol; 2023 Jan; 30(2):1648-1662. PubMed ID: 36826087 [TBL] [Abstract][Full Text] [Related]
2. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma. Xu X; Liang JH; Xu QC; Yin XY Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046 [TBL] [Abstract][Full Text] [Related]
3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity. Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W Front Genet; 2022; 13():939956. PubMed ID: 36105090 [No Abstract] [Full Text] [Related]
5. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia. Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709 [TBL] [Abstract][Full Text] [Related]
6. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer. Zhou C; Li C; Zheng Y; Huang X Front Oncol; 2022; 12():934076. PubMed ID: 36387247 [TBL] [Abstract][Full Text] [Related]
7. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
8. Identification of immune infiltration and cuproptosis-related subgroups in Crohn's disease. Yuan Y; Fu M; Li N; Ye M Front Immunol; 2022; 13():1074271. PubMed ID: 36466876 [TBL] [Abstract][Full Text] [Related]
9. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer. Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586 [TBL] [Abstract][Full Text] [Related]
10. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas. Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y Front Genet; 2022; 13():992995. PubMed ID: 36579333 [No Abstract] [Full Text] [Related]
11. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Li J; Yin J; Li W; Wang H; Ni B Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100 [TBL] [Abstract][Full Text] [Related]
12. Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature. Zhou J; Chen D; Zhang S; Wang C; Zhang L Front Genet; 2022; 13():1039983. PubMed ID: 36712848 [TBL] [Abstract][Full Text] [Related]
13. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. Chen X; Hu G; Xiong L; Xu Q Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162 [No Abstract] [Full Text] [Related]
14. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer. Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617 [TBL] [Abstract][Full Text] [Related]
15. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma. Bian Z; Fan R; Xie L Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236 [TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients. Zhang D; Wang M; Peng L; Yang X; Li K; Yin H; Xia C; Cui F; Huang H; Jin Z J Oncol; 2021; 2021():4986227. PubMed ID: 34987579 [TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma. Chen Y Front Genet; 2022; 13():912037. PubMed ID: 35937995 [No Abstract] [Full Text] [Related]
18. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z Front Immunol; 2021; 12():690056. PubMed ID: 34335594 [TBL] [Abstract][Full Text] [Related]
19. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma. Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754 [TBL] [Abstract][Full Text] [Related]
20. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Pu N; Chen Q; Gao S; Liu G; Zhu Y; Yin L; Hu H; Wei L; Wu Y; Maeda S; Lou W; Yu J; Wu W Ann Transl Med; 2019 Nov; 7(22):645. PubMed ID: 31930046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]